Quanome Technologies, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Quanome Technologies (QNME, market cap ~$20.3M) entered a stock purchase agreement dated November 4, 2026 with QAI Labs Ltd to acquire 31,579 newly issued shares (representing ~5% of QAI Labs post-issuance). Quanome will issue 6,541,236 common shares (~19% pre-issuance dilution, ~15.97% post-issuance) valued at $5M aggregate consideration, implying a $100M QAI Labs valuation. Closing is subject to customary conditions; QAI Labs remains independent, pre-commercial developer of NOVA-3 AI platform for antibody discovery.
Why this rating
Stock issuance of ~6.5M shares (~19–16% dilution) material to $20.3M cap; strategic early-stage biotech investment, not transformational. Execution risk high (QAI Labs pre-commercial); valuation and synergy unproven. Positive: diversifies quantum-life-sciences strategy. Negative: massive shareholder dilution, pre-revenue target, NASDAQ compliance risk noted.
Price action (we called it neutral)
at our read · unknown $0.39 | +10 min · unknown $0.37 ▼ 4.42% | +30 min · unknown $0.36 ▼ 8.21% | +1 hr · unknown $0.35 ▼ 8.60% | +4 hrs · unknown $0.34 ▼ 13.50% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.